Clinical Trials Logo
  1. Home
  2. Seasonal Allergic Rhinitis
  3. NCT02631551
  4. Details
NCT02631551 Clinical Trial

Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis Clinical Trial

— GSP 301-301  

Official title:
A Double-Blind, Randomized, Parallel-Group, Comparative Study to Evaluate the Efficacy, Safety and Tolerability of a Fixed Dose Combination GSP 301 Nasal Spray (NS) Compared With Placebo Nasal Spray and Individual Monotherapy Formulations (Comparators) in Subjects (Aged 12 Years and Older) With Seasonal Allergic Rhinitis (SAR)

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02631551
Other study ID # GPL/CT/2014/016/III
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2016
Est. completion date July 2016

Study information
Verified date August 2018
Source Glenmark Specialty S.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study to evaluate the efficacy and safety of GSP 301 NS compared to placebo NS and to individual monotherapies (comparators) as well as the efficacy of these monotherapies (comparators) versus placebo NS over 14 days of study treatment

Recruitment information / eligibility
Status Completed
Enrollment 1180
Est. completion date July 2016
Est. primary completion date July 2016
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria:

1. Aged 12 years and older inclusive of either sex.

2. Documented clinical history of SAR (for at least 2 years preceding the Screening Visit [Visit 1]) with exacerbations (clinical evidence of active symptoms) during the spring allergy season (tree/grass pollen)

3. A 12-hour reflective TNSS = 8 out of a possible 12 and a congestion score of = 2 for the AM assessment at the Screening Visit (Visit 1).

Exclusion Criteria:

1. Pregnant or lactating women.

2. Plans to travel outside the known pollen area for the investigative site for > 24 hours during the last 7 days of run in period.

3. History of anaphylaxis and/or other severe local reaction(s) to skin testing.

4. History of positive test for HIV, Hepatitis B or Hepatitis C infection.

5. Documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip.

6. Subjects with an active pulmonary disorder or infection.

7. Subjects with posterior subcapsular cataracts or glaucoma

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• GSP 301 NS
FDC of olopatadine HCl and mometasone furoate: 2 sprays in each nostril twice daily for 14 days
• Olopatadine HCl NS
2 sprays in each nostril twice daily for 14 days
• Mometasone furoate NS
2 sprays in each nostril twice daily for 14 days
• GSP 301 Placebo NS
2 sprays in each nostril twice daily for 14 days

Locations
Country Name City State
United States Investigational Site 3 Austin Texas
United States Investigational Site 5 Austin Texas
United States Investigational Site 8 Austin Texas
United States Investigational Site 14 Baltimore Maryland
United States Investigational Site 16 Bellevue Nebraska
United States Investigational Site 25 Centennial Colorado
United States Investigational Site 27 Cincinnati Ohio
United States Investigational Site 22 Colorado Springs Colorado
United States Investigational Site 24 Draper Utah
United States Investigational Site 10 Jupiter Florida
United States Investigational Site 1 Kerrville Texas
United States Investigational Site 11 Louisville Kentucky
United States Investigational Site 37 Marietta Georgia
United States Investigational Site 32 Medford Oregon
United States Investigational Site 30 Miami Florida
United States Investigational Site 34 Middleburg Heights Ohio
United States Investigational Site 19 Minneapolis Minnesota
United States Investigational Site 20 Mission Viejo California
United States Investigational Site 7 New Braunfels Texas
United States Investigational Site 13 Orangeburg South Carolina
United States Investigational Site 35 Portland Oregon
United States Investigational Site 18 Raleigh North Carolina
United States Investigational Site 36 Rochester New York
United States Investigational Site 21 Saint Louis Missouri
United States Investigational Site 2 San Antonio Texas
United States Investigational Site 4 San Antonio Texas
United States Investigational Site 6 San Antonio Texas
United States Investigational Site 9 San Antonio Texas
United States Investigational Site 31 San Diego California
United States Investigational Site 29 San Jose California
United States Investigational Site 12 Skillman New Jersey
United States Investigational Site 17 Spartanburg South Carolina
United States Investigational Site 15 Stockbridge Georgia
United States Investigational Site 23 Stockbridge Georgia
United States Investigational Site 28 Waco Texas
United States Investigational Site 33 Wheaton Maryland
United States Investigational Site 26 Ypsilanti Michigan

Sponsors (1)
Lead Sponsor Collaborator
Glenmark Specialty S.A.

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Change in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptoms Score (rTNSS) From Baseline to End of Treatment. Reflective Total Nasal Symptom Score (rTNSS) was calculated as the sum of 12-hour reflective scoring of the severity of four nasal symptoms (nasal congestion, rhinorrhea, nasal itching, sneezing). Subjects responded on a 4-point severity scale with scores ranging from 0 (no signs/symptoms evident) to 3 (severe signs/symptoms that is hard to tolerate). The rTNSS was calculated as the sum of the subject-reported severity scores for nasal symptoms, and value ranged from 0 (no signs/symptoms evident) to 12 (severe signs/symptoms that is hard to tolerate). 14 days
See also
  Status Clinical Trial Phase
Terminated NCT01337323 - Prospective Observational Study of Concomitant Allergic Rhinitis Treatment Patterns Among Patients Starting on Fluticasone Furoate Nasal Spray in a Retail Pharmacy Setting N/A
Completed NCT01171664 - Clinical Trial of STAHIST in Seasonal Allergic Rhinitis (SAR) Subjects Phase 2
Completed NCT00784732 - A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber Phase 2
Completed NCT00619827 - Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract Phase 1
Completed NCT00578929 - Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients Phase 3
Completed NCT00209365 - The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit N/A
Terminated NCT00223587 - Seasonal Allergic Rhinitis and Driving Ability Phase 4
Completed NCT00637455 - Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel Phase 4
Completed NCT00963599 - Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117) Phase 3
Recruiting NCT05346718 - Threshold Concentrations for Ragweed and Birch Pollen in Seasonal Allergic Rhinitis N/A
Completed NCT06126952 - Azelastine Allergen Chamber - Onset of Action Study Phase 2
Completed NCT01940146 - Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis Phase 2
Completed NCT02245360 - Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis Phase 3
Completed NCT01230619 - Vienna Challenge Chamber Study Using RV658 in Subjects With Allergic Rhinitis Phase 2
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT00561717 - A Randomized, Placebo Controlled Study to Determine the Efficacy and Speed of a Nasal Spray in Allergen Induced Seasonal Allergic Rhinitis Phase 4
Completed NCT00420082 - A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber Phase 2
Completed NCT00443495 - Phase I/IIa Study on Chitin Microparticles in Subjects Suffering From Allergic Rhinitis Phase 1/Phase 2
Completed NCT00405899 - Pilot Study of Allergy Immunotherapy and Prevention of Viral Respiratory Infections N/A
Completed NCT03097432 - Non-interventional Study to Assess the Tolerability, the Safety Profile and the Adherence of Different Up-dosing Schemes for a Sublingual Immunotherapy Treatment N/A

External Links